论文部分内容阅读
本文分析62例临床拟诊为原发性肝癌病例的5′核苷酸磷酸二酯酶同工酶第五带(以下简称5′NPDaseV)测定结果。在原发性肝癌中该同工酶的阳性率为53.1％,而在良性肝胆系统疾病及肝外肿瘤中的阳性率亦有45.5％,提示该同工酶对原发性肝癌诊断的特异性不高。又通过对部分早期原发性肝癌病例测定结果的分析及比较了该同工酶、AKP,γ-GT及AFP的阳性率与肿瘤病灶大小的关系,提示5′NPDaseV对原发性肝癌早期诊断的价值有限。
This article analyzes the results of the 5th nucleotide phosphodiesterase isoenzyme 5th band (hereinafter abbreviated as 5′NPDaseV) of 62 cases suspected of being diagnosed as primary liver cancer. The positive rate of this isoenzyme in primary liver cancer was 53.1%, while the positive rate in benign hepatobiliary disease and extrahepatic tumor was 45.5%, suggesting that this isozyme is specific for the diagnosis of primary liver cancer. not tall. Through the analysis of the results of some early primary hepatocellular carcinoma cases and the comparison of the positive rates of this isoenzyme, AKP, γ-GT and AFP with the size of tumor lesions, it is suggested that the early diagnosis of primary liver cancer with 5′NPDaseV The value is limited.